Sudarshan Pharma Industries Limited has disclosed the resignation of Sachin Vasantrai Mehta from the position of Chief Financial Officer (CFO), effective May 1, 2026. The development was formally communicated to BSE Limited by the company's Company Secretary and Compliance Officer, Nirav Shah, on May 8, 2026, in response to a query raised by the exchange on May 2, 2026, seeking additional details regarding the corporate announcement filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

CFO Resignation: Key Details

The resignation letter, dated April 27, 2026, was submitted by Sachin Vasantrai Mehta to the Board of Directors of Sudarshan Pharma Industries Limited. In his letter, Mehta tendered his resignation as CFO with effect from May 1, 2026. The company had originally filed the corporate announcement pertaining to this resignation on May 1, 2026, vide company letter no. SPIL/CS/SE/2026-2027/08 dated April 30, 2026.

The following table summarises the key details of the resignation:

Reason for Resignation and Continuing Role

In his resignation letter addressed to the Board of Directors, Mehta stated that there are no other material reasons beyond those provided for his resignation as Chief Financial Officer. Notably, Mehta clarified that he will continue to serve the company as Joint Managing Director, indicating that his association with Sudarshan Pharma Industries Limited remains intact in an executive capacity.

Mehta also expressed gratitude to his colleagues on the Board for the cooperation extended during his tenure as CFO, and requested the company to complete all necessary regulatory filings with the Stock Exchanges, Ministry of Corporate Affairs, Registrar of Companies, and all other relevant authorities.

Regulatory Compliance

The disclosure was made by Nirav Shah, Company Secretary and Compliance Officer of Sudarshan Pharma Industries Limited, in accordance with the requirements under Regulation 30 of SEBI (LODR) Regulations, 2015. The company submitted the detailed resignation letter as an enclosure to its reply, fulfilling the additional disclosure requirement sought by BSE Limited.

Sudarshan Pharma Industries Limited has disclosed its audited standalone and consolidated financial results for the quarter and financial year ended 31st March 2026. The company submitted a formal communication to the Listing Department of BSE Limited on 4th May 2026, confirming the publication of the results in compliance with applicable listing regulations.

Regulatory Filing and Newspaper Publication

The audited financial results were published as newspaper advertisements in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. The advertisements appeared in the following publications:

• Mumbai Lakshdeep
• Financial Express

The filing, referenced under communication number SPIL/CS/SE/2026-2027/09, was addressed to the BSE Limited's Listing Department at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai.

Filing Details

The key administrative details of the regulatory submission are outlined below:

About the Submission

The notice was signed by Nirav Shah, the Company Secretary and Compliance Officer of Sudarshan Pharma Industries Limited. The company's registered head office is located at 301, Aura Biplex, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai – 400092. The submission requests BSE Limited to take the enclosed newspaper advertisement on record as part of the company's ongoing disclosure obligations.